附件A2:调节质瘤的命运和潜在的治疗点
Weihai Liu1,2, Xiaofang Zhao1,2, Moksada Regmi1,2,3,4
1State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Neurosurgery, Peking University Third Hospital, Peking University, Beijing, 100191, China.
Medical oncology (Northwood, London, England)
|July 28, 2025
概括
附录素A2 (ANXA2) 是质瘤的潜在治疗点. 高ANXA2表达与生存率差相关,并且抑制它可以减少瘤的生长和通过MAPK途径传播.
科学领域:
- 神经瘤学神经瘤学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 质瘤的复发和死亡率是由积极的增殖驱动的.
- 附录素A2 (ANXA2) 是质瘤遗传干预的潜在目标.
研究的目的:
- 为了评估ANXA2在质瘤中的预后价值.
- 研究ANXA2在瘤进展中的作用及其作为治疗点的潜力.
主要方法:
- 公共质瘤数据库的生物信息学分析 (TCGA,CGGA,伦勃朗特).
- 在U87和U251细胞系的体外功能测定.
- 在体内研究评估瘤生长和扩散.
- 探索基因激活蛋白激酶 (MAPK) 信号通路.
主要成果:
- 升高的ANXA2表达与较差的质瘤存活率有关.
- 抑制ANXA2降低了质瘤细胞的增殖,入侵和瘤体积.
- 抑制ANXA2诱导了亡和改变了细胞周期的进展.
- ANXA2 影响质瘤的进展,部分通过 MAPK 途径.
结论:
- ANXA2是质瘤的显著预后标志物.
- 通过MAPK途径,ANXA2有助于质瘤的进展.
- 据了解,ANXA2是治疗质瘤的一个有前途的治疗点.
更多相关视频
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
2.8K
09:40Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
5.7K
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
02:38Mitogens and the Cell Cycle
6.9K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K